Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing Zn-doped nickel sulfide catalysts with an optimized electronic structure for enhanced hydrogen evolution reaction.

Nanoscale·2021
Same author

Clinical characteristics of low-grade tumor-related epilepsy and its predictors for surgical outcome.

Annals of clinical and translational neurology·2021
Same author

Switching Spinless and Spinful Topological Phases with Projective PT Symmetry.

Physical review letters·2021
Same author

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.

JAMA network open·2021
Same author

Polyphyllin Ⅲ-Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT.

Frontiers in pharmacology·2021
Same author

Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.

Contemporary clinical trials·2021

Related Experiment Video

Updated: Jul 9, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

A promising biomarker adaptive Phase 2/3 design - Explained and expanded.

Cong Chen1, Linda Sun1, Xuekui Zhang2

  • 1Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA.

Contemporary Clinical Trials Communications
|November 30, 2023
PubMed
Summary

This study introduces an adaptive Phase 2/3 clinical trial design for oncology drugs. It allows flexible progression based on interim biomarker analysis, optimizing drug development pathways while maintaining statistical integrity.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.8K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

Related Experiment Videos

Last Updated: Jul 9, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.8K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Biomarker-driven drug development in oncology is complex.
  • Uncertainty in biomarker effects poses challenges for traditional trial designs.

Purpose of the Study:

  • To propose a novel adaptive Phase 2/3 clinical trial design for oncology drugs.
  • To address the challenge of uncertain biomarker effects in early drug development.

Main Methods:

  • A biomarker adaptive design for Phase 2/3 oncology trials.
  • Incorporation of interim analysis for adaptive decision-making.
  • Flexible trial expansion strategies based on biomarker data.

Main Results:

  • The design allows Phase 2 to conclude, expand to Phase 3 in the same population, or expand to a broader population.
  • Each adaptive pathway maintains full alpha for hypothesis testing.
  • Overall Type I error is not inflated across different decision paths.

Conclusions:

  • This adaptive design offers flexibility in oncology drug development.
  • It efficiently utilizes biomarker information for trial progression.
  • The design ensures statistical validity throughout the adaptive process.